Drug intelligence / Profile preview

Cinalukast

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules

Overview

Cinalukast is a small molecule drug that functions as a selective antagonist of the cysteinyl leukotriene 1 (CysLT1) receptor. It primarily acts in the human airway to block the effects of leukotriene D4 (LTD4), thereby preventing inflammatory responses such as airway edema, smooth muscle contraction, and excessive mucus secretion. It has been investigated for the treatment of asthma and for the prolonged protection against exercise-induced bronchoconstriction. Additionally, it has been noted to have a role as an anti-arrhythmia drug.

Other names: cinalukast [INN]CINALUKAST [USAN]

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)

Beyond the preview

Go deeper on Cinalukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cinalukast.

Explore the full profile